De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

RenovoRx Beheer

Beheer criteriumcontroles 2/4

De CEO RenovoRx's is Shaun Bagai, benoemd in Jun2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 939.12K, bestaande uit 55.4% salaris en 44.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.22% van de aandelen van het bedrijf, ter waarde $ 310.09K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 6.8 jaar.

Belangrijke informatie

Shaun Bagai

Algemeen directeur

US$939.1k

Totale compensatie

Percentage CEO-salaris	55.4%
Dienstverband CEO	10.3yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Shaun Bagai's beloning veranderd ten opzichte van RenovoRx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$939k	US$520k	-US$10m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$841k	US$495k	-US$10m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$988k	US$323k	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$253k	US$253k	-US$4m
Dec 31 2019	US$270k	US$240k	-US$4m

Compensatie versus markt: De totale vergoeding ($USD 939.12K ) Shaun } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Shaun is gestegen terwijl het bedrijf verliesgevend is.

CEO

Shaun Bagai (47 yo)

10.3yrs

Tenure

US$939,115

Compensatie

Mr. Shaun R. Bagai has been the Chief Executive Officer and Director of RenovoRx, Inc. since June 2014. He is Secretary at RenovoRx, Inc. He joined RenovoRx in June 2014 and in his first few months has bee...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ramtin Agah	Founder	6.4yrs	US$507.76k	0.20% $ 47.5k
Shaun Bagai	CEO, Secretary & Director	10.3yrs	US$939.12k	1.22% $ 292.5k
Ronald Kocak	VP, Controller & Principal Accounting Officer	2.3yrs	geen gegevens	0% $ 0
Leesa Gentry	Chief Clinical Officer	no data	geen gegevens	0% $ 0
Ryan Witt	Senior VP and Head of Corporate Strategy & Partnerships	less than a year	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RNXT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ramtin Agah	Founder	6.4yrs	US$507.76k	0.20% $ 47.5k
Shaun Bagai	CEO, Secretary & Director	10.3yrs	US$939.12k	1.22% $ 292.5k
Una Ryan	Independent Director	11.8yrs	US$82.00k	0% $ 0
Laurence Marton	Independent Director	11.8yrs	US$77.00k	0.14% $ 33.6k
Margaret Tempero	Member of Scientific Advisory Board	1.3yrs	geen gegevens	geen gegevens
Robert Jay Spiegel	Independent Director	1.5yrs	US$173.72k	0.17% $ 41.0k
Michael Pishvaian	Member of Advisory Board	7.3yrs	geen gegevens	geen gegevens
Karyn Goodman	Member of Advisory Board	7.3yrs	geen gegevens	geen gegevens
Kirsten Macfarlane	Independent Director	6.1yrs	US$82.00k	0.17% $ 41.0k
Michel Ducreux	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RNXT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

RenovoRx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

Renovorx Appoints James Ahlers as Chief Financial Officer

Recent updates

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx, Inc. Announces Publication of Positive Early-Stage Clinical Data Relating to its Trans-Arterial Micro-Perfusion Therapy Platform

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx, Inc. announced that it has received $11.136652 million in funding

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer

RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

Price target decreased by 23% to US$8.50

RenovoRx Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

RenovoRx, Inc. announced delayed 10-Q filing

RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial

RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Price target increased by 15% to US$11.50

Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Price target decreased to US$10.00

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

RenovoRx reports Q2 results

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Renovorx Appoints James Ahlers as Chief Financial Officer

RenovoRx names new finance CFO

Renovorx Launches "The Renovorx Story" Video Series

RenovoRx, Inc., Annual General Meeting, Jun 09, 2022

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing Tiger-Pac Phase 3 Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

RenovoRx, Inc. Receives New 510(k) Clearance for its RenovoCath Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx, Inc. has completed an IPO in the amount of $16.65 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd